BioSpectrum Asia - August 2018
Get BioSpectrum Asia along with 5,000+ other magazines & newspapers
Try FREE for 7 days
Latest and past issues of 5,000+ magazines & newspapers
Digital Access. Cancel Anytime.1 Year$99.99 $49.99 Save 50%
Latest and past issues of 5,000+ magazines & newspapersDigital Access. Cancel Anytime.Get BioSpectrum Asia
1 Year $10.99
Save 7%12 issues starting from BioSpectrum Asia July 2021 Digital Access. Cancel Anytime.Buy this issue $0.99
August 2018 issue Digital Access. - Magazine Details
- In this issue
Magazine Description
In this issue
ACCELERATING IVD INNOVATIONS The increasingly ageing population, need for rapid diagnostic results, emergence and re-emergence of infectious diseases, and growing lifestyle disorders are expected to accelerate the IVD market. IVD market is constantly evolving. Mega trends such as consolidation, automation, and reimbursement policies affect every aspect of the market. The growing importance of diagnostics in patient care is expanding beyond hospitals and laboratories to homes, long term and chronic care, and other segments in healthcare. Apart from the major trends in IVD, there are other key trends like growing digitalization of healthcare to enable a more efficient patient care continuum.
Cancel Anytime [ No Commitments ]
Digital Only
3 trends to drive and shape the future of digital health
A year on, the effects of the COVID-19 pandemic on the world continue to be profound. More than 90 per cent of global executives polled by McKinsey and Company believe COVID-19 will fundamentally change their businesses, and 85 per cent predict lasting changes in customers’ preferences. Being on the frontlines of the fight against COVID-19 has placed unparalleled demands on the healthcare industry no less – and quite possibly more – than any other sector.
Making gene therapy affordable with droplet digital PCR
Gene therapy has the potential to bring relief to millions of individuals with diseases ranging from β-thalassemia to sickle cell disease across Asia and beyond.
SINGAPORE TAKES ON CANCER WITH INNOVATIVE STREAK
Although 2020 was more focused on finding solutions to fight the COVID-19 pandemic, it also pushed the boundaries of cancer prevention, diagnosis and treatment. Researchers across Asia have continued to make meaningful strides against cancer in 2020. One such remarkable example is that of Singapore. The scientific community across the country is setting new examples of innovation by focusing majorly on two aspects- chemotherapy and immunotherapy, to fight this deadly disease. While the socioeconomic burden inflicted by cancer is inevitable, Singapore’s innovative streak for developing effective treatment of cancer is set to mitigate this socioeconomic impact, and help patients maintain their quality of life, and remain productive.
“We will continue to focus on high-value targets in biopharma”
Hummingbird Bioscience, an innovative clinical-stage biotech company with its APAC headquarter in Singapore, with 60 employees is focused on developing precision therapies against hard-to-drug targets via a unique data-driven systems biology approach.
Does The World Need Global Vax Passport?
Governments around the world are exploring the potential benefits of using ‘vaccine passports’ as a way to reopening the economy by identifying and permitting only those who are protected against COVID-19. While the world awaits herd immunity, millions of vaccinated individuals across the world are eagerly anticipating trade and operational plans at the vaccination horizons. Border checkpoints are reviving vigilance around the globe and countries are exploring novel methodologies to revive international travel, an essential social and business component at present.
Shineco to pick 51% stake in Taiwan's Mayah Biological
Shineco, Inc, a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, has announced that the company and Mayah Biological Holdings, a British Virgin Islands Company headquartered in Taiwan Biomedical Park, has signed a Proposal for Purchase of Equity Interest of Mayah Biological Holding Limited, with respect to the potential purchase of at least 51 per cent equity interests in Mayah Biological by Shineco.
Heated startup race is on to capture AI-driven APAC healthcare
The Artificial Intelligence (AI) ecosystem in healthcare has grown in the recent past, as companies are looking to capitalise on the benefits provided by AI to improve patient outcomes and enable convenient, cost-effective access to healthcare solutions. In addition to the significant increase in digital penetration and internet connectivity, favourable government policies (e.g., China, Thailand and the Philippines) have been key driving factors of growth in health-tech startups across the Asia Pacific (APAC) region. AI in the APAC healthcare market is set to grow substantially due to increasing investments by Venture Capitalists in AI healthcare startups, cross-industry partnerships and collaborations.
US approves Pfizer-BioNTech COVID-19 vaccine for adolescents
The U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age.
Singapore advances stem cell tech to first-in-man clinical trial
Institutes and centres under the SingHealth Duke-NUS Academic Medical Centre (AMC) are joining hands together with Singapore’s first private cord blood bank, Cordlife Group Limited (Cordlife), to test a novel technology that expands the number of blood-forming stem cells from stored umbilical cord blood (UCB) in a first-in-man study in Singapore.
How leveraging intelligent data architecture fast tracks new drug launches
Clinical trials in medical and pharmaceutical research must deal with extreme amounts of diverse data which are generated across several institutions. A flexible data architecture can help shorten time to market.
